نوع مقاله : مقاله پژوهشی
نویسندگان
1 گروه ایمونولوژی، دانشکده پزشکی، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
2 کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
3 گروه داخلی، دانشکده پزشکی، مرکز تحقیقات لیشمانیوز، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
4 گروه آمار زیستی و اپیدمیولوژی، دانشکده بهداشت، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
5 مرکز تحقیقات سلولی و مولکولی، دانشگاه علوم پزشکی سبزوار، سبزوار، ایران
چکیده
زمینه و هدف: ویروس جدید SARS-CoV-2، عامل بیماری کرونا ویروس 2019 (کووید 19) است. این ویروس به بیش از 220 کشور جهان گسترش پیداکرده و بیش از 700 میلیون نفر به این بیماری مبتلا شدهاند. این مطالعه بهمنظور بررسی فراوانی سرمی آنتیبادیهای IgM و IgG ضدSARS-CoV-2 در بین کارکنان بهداشتی و درمانی بیمارستان واسعی سبزوار انجام شد.
مواد و روشها: پژوهش حاضر از نوع مقطعی و توصیفی-تحلیلی و بر روی 165 نفر از کارکنان مراقبتهای بهداشتی و درمانی بیمارستان واسعی سبزوار در اسفندماه 1399 انجامشدهاست. جهت مقایسه، افراد موردمطالعه در 3 گروه کادر درمانی (95 نفر)، خدماتی (44 نفر) و اداری (26 نفر) قرار گرفتند. از هر شرکتکننده، مقدار 5 میلیلیتر خون، جمعآوری شد. سپس، با روش الایزا سطح سرمی آنتیبادیهای IgM/IgG ضد SARS-CoV-2 اندازهگیریشد. دادهها در نرمافزار SPSS نسخه 24 آنالیز و 0.05P≤ بهعنوان سطح معنیداری در نظر گرفته شد.
یافتهها: از مجموع 165 شرکتکننده، 58.2% زن و 41.8% مرد بودند. میانگین سنی افراد 7.76±35.84 بود. نتیجه آزمایش آنتیبادی IgM ضد SARS-CoV-2 در 9 نفر (5.5 درصد) و آزمایش آنتیبادی IgG ضد SARS-CoV-2 در 106 نفر (64.2 درصد) مثبت بود. همچنین، کادر خدماتی و کارکنان درمانی بهطور قابلتوجهی بیشتر از کارکنان اداری آزمایش آنتیبادی مثبت داشتند (p=0.03).
نتیجهگیری: طبق نتایج به دست آمده، 5.5% افراد موردمطالعه عفونت فعال و 64.2% افراد سابقه عفونت با ویروس SARS-CoV-2 داشتند. دلیل این موضوع میتواند مواجهه بیشتر کادر بهداشتی-درمانی، فقدان واکسن مؤثر و همچنین کمبود تجهیزات پیشگیریکننده از آلودگی با ویروس مذکور باشد.
تازه های تحقیق
https://scholar.google.com/citations?hl=en&user=lBfBEnIAAAAJ
https://pubmed.ncbi.nlm.nih.gov/?term=Mojadadi,+Mohammad+Shafi%5bAuthor%5d&sort=date
https://scholar.google.com/citations?view_op=list_works&hl=en&user=eTGn72kAAAAJ
https://pubmed.ncbi.nlm.nih.gov/?term=hosein+sedaghati
https://scholar.google.com/citations?hl=en&user=Ns7XztYAAAAJ
https://scholar.google.com/citations?hl=en&user=Wt54-cQAAAAJ
https://pubmed.ncbi.nlm.nih.gov/?term=Neda+Mahdavifar++
https://scholar.google.com/citations?user=NnuulHIAAAAJ&hl=en
https://pubmed.ncbi.nlm.nih.gov/?term=Shobeiri,+Saeideh+sadat%5bAuthor%5d
کلیدواژهها
موضوعات
عنوان مقاله [English]
Seroprevalence and Determinants of SARS-CoV-2 Antibodies Among Healthcare Workers in Sabzevar Vasei Hospital
نویسندگان [English]
- Mohammad Shafi Mojadadi 1
- Hossein Sedaghati 2
- Abolfazl Shakiba 3
- Neda Mahdavifar 4
- Saeideh sadat Shobeiri 5
1 Department of Immunology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.
2 Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
3 Department of Internal Medicine, Faculty of Medicine, Leishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
4 Department of Biostatistics and Epidemiology, Faculty of Health, Sabzevar University of Medical Sciences, Sabzevar, Iran
5 Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
چکیده [English]
Introduction: The novel SARS-CoV-2 virus is the causative agent of coronavirus disease 2019 (COVID-19). This virus has spread to over 220 countries, infecting more than 700 million individuals worldwide. This study aimed to investigate the serum prevalence of IgM and IgG anti-SARS-CoV-2 antibodies among healthcare workers at Sabzevar Vasei Hospital.
Materials and Methods: This cross-sectional descriptive-analytical study was conducted on 165 healthcare workers at Sabzevar Vasei Hospital in March 2021. Participants were divided into three groups for comparison: medical staff (95 individuals), service staff (44 individuals), and administrative staff (26 individuals). A 5 mL blood sample was collected from each participant, and serum levels of IgM and IgG antibodies against SARS-CoV-2 were measured using ELISA. Data were analyzed using SPSS software (version 16), with statistical significance set at P ≤ 0.05.
Results: Of a total of 165 participants, 58.2% were women and 41.8% men, with a mean age of 35.84 ± 7.76 years. IgM antibodies against SARS-CoV-2 were positive in 9 individuals (5.5%), while IgG antibodies were positive in 106 individuals (64.2%). Additionally, service staff and medical staff had significantly higher rates of positive antibody tests compared to administrative staff (P = 0.03).
Conclusion: The findings indicate that 5.5% of participants had an active infection, while 64.2% had evidence of a prior SARS-CoV-2 infection. This higher seroprevalence among healthcare workers may be attributed to greater occupational exposure, the lack of an effective vaccine at the time, and insufficient infection prevention equipment.
کلیدواژهها [English]
- Antibodies
- COVID-19
- SARS-CoV-2
- Seroprevalence
- organization(WHO) wh. Coronavirus disease (COVID-19) Pandemic 2022 [Available from: https://extranet.who.int/pqweb/vitro-diagnostics/coronavirus-disease-covid-19-pandemic %E2%80%94-emergency-use-listing-procedure-eul-open.
- Mojadadi M-S, Aram M, Shahraini R, Shakiba A, Shobeiri SS. Blood-Based Inflammatory Indices in COVID-19 Patients with Different Degrees of Lung Involvement. Journal of Isfahan Medical School. 2024;41(752):1226-34. doi: 48305/jims.v41.i752.1226
- Bastani M-N, Makvandi M, Moradi M, Haghighi SB, Rostami M, Nasimzadeh S, et al. Comprehensive assessment of COVID-19 case fatality rate and influential factors in Khuzestan Province, Iran: a two-year study. Journal of Health, Population and Nutrition. 2024;43(1):193. https://doi.org/10.1186/s41043-024-00673-6
- Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet]. 2022.
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. Jama. 2020;324(8):782-93. https://doi.org/10.1001/jama.2020.12839
- Tabrizi JS, Letaief M, Mashhadi Abdolahi H, Rezapour R, Alboksmaty A, Farahbakhsh M. Safety of health workers during the COVID-19 pandemic and beyond: piloting WHO framework in Iran. Journal of Health, Population and Nutrition. 2025;44(1):29. https://doi.org/10.1186/s41043-025-00749-x
- Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health-Europe. 2021;1:100013, DOI: 10.1016/j.lanepe.2020.100013...
- Grant JJ, Wilmore SM, McCann NS, Donnelly O, Lai RW, Kinsella MJ, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. Infection Control & Hospital Epidemiology. 2021;42(2):212-4, DOI: https://doi.org/10.1017/ice.2020.402.
- Rudberg A-S, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nature communications. 2020;11(1):1-8. DOI: 10.1038/s41467-020-18848-0.
- Balou HA, Yaghubi Kalurazi T, Joukar F, Hassanipour S, Shenagari M, Khoshsorour M, et al. High seroprevalence of SARS-CoV-2 (COVID-19)-Specific antibodies among healthcare workers: a cross-sectional study in guilan, Iran. Journal of Environmental and Public Health. 2021;2021. DOI: 1155/2021/9081491.
- Venugopal U, Jilani N, Rabah S, Shariff MA, Jawed M, Batres AM, et al. SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: A cross-sectional analysis during the COVID-19 pandemic. International Journal of Infectious Diseases. 2021;102:63-9. DOI: 1016/j.ijid.2020.10.036.
- Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. The Lancet Infectious Diseases. 2021;21(4):473-81. DOI: 10.1016/ S1473-3099(20)30858-6
- Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. 2020;396(10250):535-44. DOI: 10.1016/ S0140-6736(20)31483-5.
- Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfusion. 2021;19(3):181. doi: 2450/2021.0324-20.
- Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020. Jama. 2020;323(23):2425-7. doi: 2450/2021.0324-20.
- Song S-K, Lee D-H, Nam J-H, Kim K-T, Do J-S, Kang D-W, et al. IgG seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu, Korea. Journal of Korean medical science. 2020;35(29). DOI: 3346/jkms.2020.35.e269.
- Tsurkalenko O, Bulaev D, O’Sullivan MP, Snoeck C, Ghosh S, Kolodkin A, et al. Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE). BMC Infectious Diseases. 2024;24(1):179. DOI: https://doi.org/10.1186/s12879-024-09055-z.
- Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jimenez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nature communications. 2020;11(1):1-9. DOI: 10.1038/s41467-020-17318-x.
- Iqbal J, Hasan Z, Habib MA, Malik AA, Muhammad S, Begum K, et al. Evidence of rapid rise in population immunity from SARS-CoV-2 subclinical infections through pre-vaccination serial serosurveys in Pakistan. Journal of Global Health. 2025;15:04078. doi: 7189/jogh.15.04078.
- Signorelli C, Scognamiglio T, Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Bio Medica: Atenei Parmensis. 2020;91(Suppl 3):175. DOI: 23750/abm.v91i3-S.9511.
- Rostami A, Sepidarkish M, Leeflang MM, Riahi SM, Shiadeh MN, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2021;27(3):331-40. DOI: 1016/j.cmi.2020.10.020.
- Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SSH, Rezvani SM, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis. 2021;27(2):636-8. https://doi.org/10.3201/eid2702.201960
- Byambasuren O, Dobler CC, Bell K, Rojas DP, Clark J, McLaws M-L, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. PloS one. 2021;16(4):e0248946. https://doi.org/10.1371/journal.pone.0248946.
)